PD-L1 expression in advanced melanoma was thought to be correlated with response to monoclonal antibodies targeting PD-1/PD-L1 pathway, moreover, the sensitivity to PD-1/PD-L1 blocking antibodies seemed to be more robust in patients whose tumors express PD-L1 [88, 89]. Here, PDCD1 is linked to melanoma.